Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC populationOral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and systemic potential effects of NBTXR3.
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program at ASTRO21 itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC population
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders
Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders
Data suggest abscopal effect in some patients (i.e., reduction in non-injected non-irradiated lesions)
To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)